Literature DB >> 22814117

Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients.

J Saltytė Benth1, K-M Myhr, K I Løken-Amsrud, A G Beiske, K S Bjerve, H Hovdal, R Midgard, T Holmøy.   

Abstract

BACKGROUND/AIM: 25-Hydroxyvitamin D (25(OH)D) levels are suggested to influence the susceptibility and risk of disease progression in multiple sclerosis (MS). Seasonal fluctuation of 25(OH)D levels may differ in magnitude between individuals. The purpose of this paper was to model the seasonal fluctuation of vitamin D in Norwegian MS patients and to examine to which extent one single 25(OH)D measurement predicts the level at other time points throughout the year.
METHODS: During December 2004 and July 2008, 762 serum samples were collected from 92 Norwegian relapsing-remitting MS patients. Time series analysis and multivariate modelling techniques were used to model seasonal fluctuations and intra- and inter-individual variations in 25(OH)D values.
RESULTS: Most patients reached their lowest 25(OH)D level in March/April and the highest in July/August. There were substantial intra-individual variations in the extent of seasonal fluctuation, with 36.6% of explainable variation in seasonally adjusted 25(OH)D levels (on a logarithmic scale) attributable to the patient level. The remaining 63.4% could be accounted for by sources of inter-individual variation. Both the total and inter-individual variabilities were lowest in February, and the prediction interval in this month was up to 26% narrower compared to other months. The prediction intervals would be at least 21% wider with only one observation available per patient.
CONCLUSIONS: The seasonal fluctuations of 25(OH)D levels in Norwegian relapsing-remitting MS patients are subject to pronounced intra- and inter-individual variation. The most representative measurements of 25(OH)D levels are taken in February.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814117     DOI: 10.1159/000339360

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  7 in total

1.  In the search for reliable biomarkers for the early diagnosis of autism spectrum disorder: the role of vitamin D.

Authors:  Afaf El-Ansary; John J Cannell; Geir Bjørklund; Ramesa Shafi Bhat; Abeer M Al Dbass; Hanan A Alfawaz; Salvatore Chirumbolo; Laila Al-Ayadhi
Journal:  Metab Brain Dis       Date:  2018-03-01       Impact factor: 3.584

Review 2.  A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis.

Authors:  Beatriz Pozuelo-Moyano; Julián Benito-León; Alex J Mitchell; Jesús Hernández-Gallego
Journal:  Neuroepidemiology       Date:  2012-12-18       Impact factor: 3.282

3.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

4.  Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.

Authors:  Anne-Hilde Muris; Joost Smolders; Linda Rolf; Lieke J J Klinkenberg; Noreen van der Linden; Steven Meex; Jan Damoiseaux; Raymond Hupperts
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

5.  High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.

Authors:  Trygve Holmøy; Jonas Christoffer Lindstrøm; Erik Fink Eriksen; Linn Hofsøy Steffensen; Margitta T Kampman
Journal:  BMC Neurol       Date:  2017-04-04       Impact factor: 2.474

6.  Seasonal variations of 25-OH vitamin D serum levels in Multiple Sclerosis patients with relapse using MRI.

Authors:  Sharareh Sanei Sistani; Ali Moghtaderi; Ali Reza Dashipoor; Maryam Ghaffarpoor; Bahareh Heshmat Ghahderijani
Journal:  Eur J Transl Myol       Date:  2019-08-08

Review 7.  An Update on Vitamin D and Disease Activity in Multiple Sclerosis.

Authors:  Joost Smolders; Øivind Torkildsen; William Camu; Trygve Holmøy
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.